Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.

Abstract:

:We propose a new adaptive threshold detection and enrichment design in which the biomarker threshold is adaptively estimated and updated by optimizing a trade-off between the size of the biomarker positive population and the magnitude of the treatment effect in that population. Enrichment is based on an enrollment criterion that accounts for the uncertainty in estimation of the threshold. Early termination for futility is allowed based on predictive success probability. Valid testing and estimation techniques for the treatment effect overall and inpatient subgroups are studied. Simulations and an example demonstrate advantages of the proposed design over existing designs.

journal_name

J Biopharm Stat

authors

Wang T,Wang X,George SL,Zhou H

doi

10.1080/10543406.2020.1832110

subject

Has Abstract

pub_date

2020-11-11 00:00:00

pages

1-17

eissn

1054-3406

issn

1520-5711

pub_type

杂志文章
  • Subgroup analyses in randomized clinical trials: statistical and regulatory issues.

    abstract::Recently, two CPMP Points to Consider, one on adjustment for baseline covariates and the other on multiplicity issues in clinical trials, have included recommendations on the use of subgroup analysis for regulatory purposes. However, despite their regular use and regulatory attention, the validity and nature of subgro...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200067988

    authors: Grouin JM,Coste M,Lewis J

    更新日期:2005-01-01 00:00:00

  • Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.

    abstract::The study of drug combinations has become important in drug development due to its potential for efficacy at lower, less toxic doses and the need to move new therapies rapidly into clinical trials. The goal is to identify which combinations are additive, synergistic, or antagonistic. Although there exists statistical ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400902964019

    authors: Fang HB,Tian GL,Li W,Tan M

    更新日期:2009-07-01 00:00:00

  • Analysis of recurrent hypoglycemic events.

    abstract::Hypoglycemia is a major safety concern for diabetic patients. Hypoglycemic events can be modeled based on time to recurrent events or count data. In this article, we evaluated a gamma frailty model with variance estimated by the inverse of observed Fisher information matrix, a gamma frailty model with the sandwich var...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1765370

    authors: Ma C,Qu Y,Fu H

    更新日期:2020-05-18 00:00:00

  • Generalized estimating equations for multivariate response with the variates having different distributions.

    abstract::This paper addresses the problem of analyzing multivariate response with the variates having different distributions. We use the generalized estimating equations proposed by Prentice and Zhao (1) to estimate mean and covariance parameters. Wald statistics are used to test hypotheses about the parameters. Data from a t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835129

    authors: May WL,Johnson WD

    更新日期:1996-05-01 00:00:00

  • Interval estimation of the proportion ratio in repeated binary measurements under a stratified randomized clinical trial with noncompliance.

    abstract::The proportion ratio (PR) of a positive response between an experimental treatment and a standard treatment (or placebo) is often used to measure the relative treatment efficacy in a randomized clinical trial (RCT). For ethical reasons, it is almost inevitable to encounter some patients not complying with their assign...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.508139

    authors: Lui KJ,Chang KC

    更新日期:2012-01-01 00:00:00

  • Impact of model misspecification at design (and/or) estimation step in population pharmacokinetic studies.

    abstract::The aim of this work is to quantitatively assess the impact of structural model misspecifications on the estimates of mean and interindividual variability of clearance in the context of population approaches. This assessment is conducted from simulated datasets. Our results show that impact magnitude of model misspeci...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120028516

    authors: Merlé Y,Aouimer A,Tod M

    更新日期:2004-02-01 00:00:00

  • Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

    abstract::Frequentist design for two-arm randomized Phase II clinical trials with outcomes from the exponential dispersion family was proposed previously, where the total sample sizes are minimized under multiple constraints on the standard errors of the estimated group means and their difference. This design was generalized fr...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1402779

    authors: Jiang W,Wick JA,He J,Mahnken JD,Mayo MS

    更新日期:2018-01-01 00:00:00

  • Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

    abstract::Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intui...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293075

    authors: Diao G,Zeng D,Ibrahim JG,Rong A,Lee O,Zhang K,Chen Q

    更新日期:2017-01-01 00:00:00

  • Joint bent-cable Tobit models for longitudinal and time-to-event data.

    abstract::In this article, we show how to estimate a transition period for the evolvement of drug resistance to antiretroviral (ARV) drug or other related treatments in the framework of developing a Bayesian method for jointly analyzing time-to-event and longitudinal data. For HIV/AIDS longitudinal data, developmental trajector...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1321006

    authors: Dagne GA

    更新日期:2018-01-01 00:00:00

  • On identifying effective and superior drug combinations via Holm's procedure based on the min tests.

    abstract::In this paper I consider a problem of identifying all effective and superior drug combinations. I formulate this problem in terms of a family of hypotheses and propose a two-stage method to solve it. The first stage uses individual p-values obtained via the Min tests, whereas Holm's approach is employed in the second ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802622469

    authors: Soulakova JN

    更新日期:2009-01-01 00:00:00

  • Substantial evidence of effect.

    abstract::Pressures for rapid drug development, especially for treatments that may affect public health significantly, drive a need to reconsider what is necessary to establish the "substantial evidence" of efficacy and safety required for regulatory approval. The concept of substantial evidence of effect can be stated fairly s...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-120005740

    authors: Gould AL

    更新日期:2002-02-01 00:00:00

  • Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials.

    abstract::Multipopulation tailoring trials provide a trial design option that supports the realization of tailored therapeutics or personalized medicine. Several recent publications have focused on statistical and clinical considerations that arise in these trials that are designed to study the overall treatment effect in a pop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2013.856025

    authors: Millen BA,Dmitrienko A,Song G

    更新日期:2014-01-01 00:00:00

  • Bayesian pooling versus sequential integration of small preclinical trials: a comparison within linear and nonlinear modeling frameworks.

    abstract::Bayesian sequential integration is an appealing approach in drug development, as it allows to recursively update posterior distributions as soon as new data become available, thus considerably reducing the computation time. However, preclinical trials are often characterized by small sample sizes, which may affect the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1776312

    authors: La Gamba F,Jacobs T,Serroyen J,Geys H,Faes C

    更新日期:2020-06-18 00:00:00

  • Bayesian approach for cure models with a change-point based on covariate threshold: application to breast cancer data.

    abstract::In this study, a Bayesian approach was suggested to estimate a change-point according to a covariate threshold when some patients never experienced the event of interest. Gibbs sampler algorithm with latent binary cure indicators was used to simplify the implementation of Markov chain Monte Carlo method. Then, the acc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1632877

    authors: Shamsi F,Baghestani AR,Binesh F

    更新日期:2020-03-01 00:00:00

  • Dunnett's many-to-one test and least square means.

    abstract::Dunnett's many-to-one test is used frequently today, especially in dose-finding studies. Using Dunnett's test, the Type I error level for the comparison between the raw mean of the control and the raw means of the study drug groups can be exactly calculated for the normal data. However, this computability depends on t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120017723

    authors: Shun Z,Silverberg A,Chang CK,Ouyang P

    更新日期:2003-02-01 00:00:00

  • Planning survival studies to compare a treatment to an active control.

    abstract::Rubinstein et al. presented a procedure for determining the required duration of accrual for a clinical trial comparing the survival distributions of two treatments using a classical hypothesis testing formulation. Here their testing procedure is modified in two ways. First, the asymptotic variances used in computatio...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409308835056

    authors: Bristol DR

    更新日期:1993-09-01 00:00:00

  • Power and sample size for the S:T repeated measures design combined with a linear mixed-effects model allowing for missing data.

    abstract::Tango (Biostatistics 2016) proposed a new repeated measures design called the S:T repeated measures design, combined with generalized linear mixed-effects models and sample size calculations for a test of the average treatment effect that depend not only on the number of subjects but on the number of repeated measures...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293083

    authors: Tango T

    更新日期:2017-01-01 00:00:00

  • A bias correction in testing treatment efficacy under informative dropout in clinical trials.

    abstract::In clinical trials of drug development, patients are often followed for a certain period of time, and the outcome variables are measured at scheduled time intervals. The main interest of the trial is the treatment efficacy at a prespecified time point, which is often the last visit. In such trials, patient dropout is ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903242753

    authors: Kong F,Chen YF,Jin K

    更新日期:2009-11-01 00:00:00

  • Symmetry in square contingency tables: tests of hypotheses and confidence interval construction.

    abstract::Bowker's test, a generalization of McNemar's test, performs well under the hypothesis of symmetry, but the estimator of variance used in the test is biased when the table is asymmetric and this calls into question the test's performance in non-null situations. We seek an alternative to Bowker's test in search of metho...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100104195

    authors: May WL,Johnson WD

    更新日期:2001-02-01 00:00:00

  • Estimation of the combined response to treatment in multicenter trials.

    abstract::Analyses of multicenter trials consider the estimated treatment effect differences of the individual centers and combine them into an estimate of the overall treatment effect. There has been much debate in the literature concerning the best way to combine these treatment effect differences. We emphasize that first of ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:

    authors: Dragalin V,Fedorov V,Jones B,Rockhold F

    更新日期:2001-11-01 00:00:00

  • A global model to define the behavior of partial agonists (bell-shaped dose-response inducers) in pharmacological evaluation of activity in the presence of the full agonist.

    abstract::The dose-response models for full agonists and for a particular type of partial agonist can be described by sigmoidal curves and bell-shaped curves, respectively. The methods currently used to evaluate the interaction of a full agonist and a partial agonist require a large number of experimental units and base their a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409808835266

    authors: Ghosh K,Shen ES,Arey BJ,López FJ

    更新日期:1998-11-01 00:00:00

  • Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

    abstract::We extend the development of the expression of the Fisher information matrix in nonlinear mixed effects models for designs evaluation. We consider the dependence of the marginal variance of the observations with the mean parameters and assume an heteroscedastic variance error model. Complex models with interoccasions ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120019267

    authors: Retout S,Mentré F

    更新日期:2003-05-01 00:00:00

  • Nonparametric step-down test procedures for finding minimum effective dose.

    abstract::Nonparametric versions of normal theory step-down multiple-test procedures for inferring minimum effective dose (see Tamhane et al. (1)) were developed and studied by Monte Carlo simulation. Two types of step-down testing procedures were examined. For both procedures, pairwise, linear, or Helmert contrasts of mean ran...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101173

    authors: Sidik K,Morris RW

    更新日期:1999-05-01 00:00:00

  • Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control.

    abstract::In a clinical dose finding study with active control a new drug with several dose levels is compared with an active comparator drug. The main focus of such studies often lies on the estimation of a target dose that leads to the same efficacy as the control. This article investigates the finite sample properties of the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.920343

    authors: Helms HJ,Benda N,Friede T

    更新日期:2015-01-01 00:00:00

  • FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.

    abstract::The Food and Drug Administration of the United States issued a draft guidance on adaptive design clinical trials in February 2010. This draft guidance has attracted a lot of attention because of the increasing interest in adaptive trials by the pharmaceutical industry in recent years. In this paper, we report on highl...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.514456

    authors: Chuang-Stein C,Beltangady M

    更新日期:2010-11-01 00:00:00

  • Bias estimation in method comparison studies.

    abstract::A test and a reference analytical method are usually compared for agreement based on paired data obtained from several independent subjects. Bias between two methods can be classified as constant and proportional. In this article, we provide an approach for maximum likelihood estimation of total bias between two metho...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200035450

    authors: Magari RT

    更新日期:2004-11-01 00:00:00

  • Optimal population designs for PK models with serial sampling.

    abstract::In various pharmaceutical applications, repeated measurements are taken from each subject, and model parameters are estimated from the collected data. Examples include dose response modeling and PK/PD studies with serial blood sampling, among others. The quality of the information in an experiment is reflected in the ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-200040853

    authors: Gagnon R,Leonov S

    更新日期:2005-01-01 00:00:00

  • Dual composite reference standards (dCRS) in molecular diagnostic research: A new approach to reduce bias in the presence of Imperfect reference.

    abstract::A main challenge in molecular diagnostic research is to accurately evaluate the performance of a new nucleic acid amplification test when the reference standard is imperfect. Several approaches, such as discrepant analysis, composite reference standard (CRS) method, or latent class analysis (LCA), are commonly applied...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2018.1428613

    authors: Tang S,Hemyari P,Canchola JA,Duncan J

    更新日期:2018-01-01 00:00:00

  • Comparison of concordance correlation coefficient and coefficient of individual agreement in assessing agreement.

    abstract::In method comparison and reliability studies, it is often important to assess agreement between multiple measurements made by different methods, devices, laboratories, observers, or instruments. For continuous data, the concordance correlation coefficient (CCC) is a popular index for assessing agreement between multip...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400701329497

    authors: Barnhart HX,Lokhnygina Y,Kosinski AS,Haber M

    更新日期:2007-01-01 00:00:00

  • Statistical Properties of the Design for Simultaneous Global Drug Development Program.

    abstract::Recently, a design was proposed for the Simultaneous Global Drug Development Program (SGDDP) to assess the impact of ethnic factors on the effect of a new treatment for a targeted ethnic (TE) population. It used weighted Z tests to combine the information collected from the TE and non-TE (NTE) subgroups in the SGDDP b...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.971166

    authors: Liu K,Yuan Z,Chen G,Huang Q,Wenrich J

    更新日期:2015-01-01 00:00:00